TiGenix , a leader in the field of cell therapy, announced today that during the first half of 2013 the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect , the only approved cell therapy in Europe, and of the company's ... (more)
http://www.biospace.com/news_story.aspx?StoryID=286562&full=1
http://www.biospace.com/news_story.aspx?StoryID=286562&full=1
No comments:
Post a Comment